Scholar Rock Q1 net loss widens as expenses rise

Scholar Rock Holding

07/05/2026 12:25

Overview

U.S. biopharma firm reported Q1 net loss widened as no revenue was recorded

Operating expenses rose in Q1 2026, driven by R&D and commercial launch preparations

Result Drivers

HIGHER R&D SPENDING - Increased research and development costs contributed to higher operating expenses in Q1 2026

COMMERCIAL LAUNCH PREPARATIONS - General and administrative expenses rose as company prepared for potential U.S. launch of apitegromab

Company press release: ID:nBwbR8hmZa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 EPS
-$0.83
Q1 Net Income
-$105.51 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Scholar Rock Holding Corp is $58.00, about 23.1% above its May 6 closing price of $47.11

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)